Given these observations it has been recommended that identifying germline BRCA1/BRCA2 mutation carriers may have important implications in the management of women with ovarian cancer as targeted therapies such as PARP inhibitors are introduced into clinical settings [9]. The gene discussed is BRCA2; the disease is ovarian carcinoma.